Xin Zhai

846 citations

66 papers · 695 indexed · h-index 16

Organic Chemistry top 5%
- Synthesis and biological activity 22
- Quinazolinone synthesis and applications 14
- Click Chemistry and Applications 10
Toxicology top 10%
Oncology
- Lung Cancer Research Studies 8
Molecular Biology
- Cancer therapeutics and mechanisms 20
- Sphingolipid Metabolism and Signaling 6
- PI3K/AKT/mTOR signaling in cancer 4
Pulmonary and Respiratory Medicine
- Lung Cancer Treatments and Mutations 17

Co-authors: Ping Gong Ming Guo Daiying ZuoNan JiangJunjie Ma Yanfang Zhao Wufu Zhu Wenfeng Gou
Cited by: Organic Chemistry Toxicology Oncology
Journals: Science Advances (1 paper)Molecules (2 papers)Cancer Letters (1 paper)
Partner nations: China Singapore

In The Last Decade

Xin Zhai

65 papers receiving 690 citations

Peers

Countries citing papers authored by Xin Zhai

Since Specialization

Citations

This map shows the geographic impact of Xin Zhai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xin Zhai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xin Zhai more than expected).

Fields of papers citing papers by Xin Zhai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xin Zhai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xin Zhai. The network helps show where Xin Zhai may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Xin Zhai, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Xin Zhai Line = papers co-authored together Xin Zhai links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Rational design and identification of potent imidazole-fused Autotaxin inhibitors for treatment of idiopathic pulmonary fibrosis European Journal of Medicinal Chemistry ·Bing Zhao,Sha Xu,Xiujian Wei,You Li,Shuaiyong Qu,Hongrui Lei,Xin Zhai	2025	0
2	Rational design and synthesis of 6-(piperazin-1-yl)imidazo[1,2-b]pyridazine derivatives as dual FXR/PPARδ agonists for treatment of pulmonary fibrosis European Journal of Medicinal Chemistry ·Lingfeng Yue,Nan Jiang,Xue Fan,Sha Xu,Ren Yi,Hongrui Lei,Xin Zhai	2025	1
3	Research progress on covalent inhibitors targeting alkaline amino acids Bioorganic Chemistry ·Bing Zhao,Sha Xu,Shiqing Zhou,Xiaolong Jiang,Ailin Jiang,Hongrui Lei,Xin Zhai	2025	1
4	Development of potent indole-3-carboxamide autotaxin inhibitors with preferred lipophilicity for in vivo treatment of pulmonary fibrosis European Journal of Medicinal Chemistry ·Deyi Ma,Nan Jiang,Jiachen Zhang,Hongrui Lei,Xin Zhai	2025	1
5	Recent advances and challenges of revolutionizing drug-resistant tuberculosis treatment European Journal of Medicinal Chemistry ·Xiujian Wei,Lingfeng Yue,Bing Zhao,Nan Jiang,Hongrui Lei,Xin Zhai	2024	11
6	Discovery of first-in-class DOT1L inhibitors against the R231Q gain-of-function mutation in the catalytic domain with therapeutic potential of lung cancer Acta Pharmaceutica Sinica B ·Zehui Tan,Ning Guo,Zhi Cao,Shuyu Liu,Jiayu Zhang,Deyi Ma,Jiahao Zhang,Wencai Lv,Nan Jiang,Linghe Zang,Lihui Wang,Xin Zhai	2024	3
7	Gain-of-function mutations in the catalytic domain of DOT1L promote lung cancer malignant phenotypes via the MAPK/ERK signaling pathway Science Advances ·J. Zhang,Ting Yang,Mei Han,Xiaoxuan Wang,Weiming Yang,Ning Guo,Yong Ren,Wei Cui,S. Li,Yongshan Zhao,Xin Zhai,Lina Jia,Jingyu Yang,Chunfu Wu,Lihui Wang	2023	12
8	Development of a new type of multi-functional mechanochromic luminescence material by infusing a phenyl rotator into the structure of 3,4-diphenylmaleic anhydride New Journal of Chemistry ·Zexin Wang,Liwei Chen,Xiang Lin,Wei Liu,Jun Han,Nannan Chen,Hong Jiang,Shitao Sun,Zhenli Li,Jinle Hao,Bin Lin,Renfu Li,Xueyuan Chen,Xin Zhai,Lijun Xie	2022	2
9	Design, synthesis and anti-tumor efficacy of novel phenyl thiazole/triazole derivatives as selective TrkA inhibitors Bioorganic & Medicinal Chemistry ·Xinyu Wang,Zehui Tan,Fuyi Wang,Jiahao Zhang,Juanjuan Yang,Shuyu Liu,Nan Jiang,Xin Zhai	2022	1
10	Design, synthesis and antitumor evaluation of ATP dual-mimic 2,4-diarylaminopyrimidine and aminoindazole conjugates as potent anaplastic lymphoma kinase inhibitors European Journal of Medicinal Chemistry ·Jing Yang,Deyi Ma,Shuyu Liu,Zehui Tan,Ming Guo,Zhi Cao,Jiahao Zhang,Xin Zhai	2022	3
11	Harmine-inspired design and synthesis of benzo[d]imidazo[2,1-b]thiazole derivatives bearing 1,3,4-oxadiazole moiety as potential tumor suppressors Bioorganic & Medicinal Chemistry ·Tianming Zhao,Yang Yu,Jing Yang,Youbao Cui,Zhi Cao,Daiying Zuo,Xin Zhai	2021	14
12	Discovery and antitumor activity of Benzo[d]imidazol-containing 2,4-diarylaminopyrimidine analogues as ALK inhibitors with mutation-combating effects Bioorganic & Medicinal Chemistry ·Zheng Li,Ming Guo,Meng Cao,Tianming Zhao,Mingzhu Li,Xin Zhai	2021	7
13	Structural and PK-guided identification of indole-based non-acidic autotaxin (ATX) inhibitors exhibiting high in vivo anti-fibrosis efficacy in rodent model European Journal of Medicinal Chemistry ·Hongrui Lei,Zhi Cao,Huinan Wu,Tong Li,Xinyu Wang,Yuxiang Chen,Enlong Ma,Lixin Sun,Xin Zhai	2021	9
14	Nucleoside and Non-Nucleoside DOT1L Inhibitors: Dawn of MLLrearranged Leukemia Mini-Reviews in Medicinal Chemistry ·Meng Cao,Tong Li,Yuxiang Chen,Xin Zhai	2021	5
15	Fragment-based modification of 2,4-diarylaminopyrimidine derivatives as ALK and ROS1 dual inhibitors to overcome secondary mutants Bioorganic & Medicinal Chemistry ·Minglin Zhu,Wei Li,Tianming Zhao,Yuxiang Chen,Tong Li,Shangfei Wei,Ming Guo,Xin Zhai	2020	10
16	CD74-ROS1 G2032R mutation transcriptionally up-regulates Twist1 in non-small cell lung cancer cells leading to increased migration, invasion, and resistance to crizotinib Cancer Letters ·Wenfeng Gou,Xuejiao Zhou,Zi Liu,Lijing Wang,Jiwei Shen,Xiaobo Xu,Zengqiang Li,Xin Zhai,Daiying Zuo,Yingliang Wu	2018	46
17	Dual potent ALK and ROS1 inhibitors combating drug-resistant mutants: Synthesis and biological evaluation of aminopyridine-containing diarylaminopyrimidine derivatives European Journal of Medicinal Chemistry ·Ming Guo,Daiying Zuo,Jun‐Long Zhang,Lingyun Xing,Wenfeng Gou,Feng Jiang,Nan Jiang,Dajun Zhang,Xin Zhai	2018	24
18	5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-4-(4-((4-methylpiperazin-1-yl)methyl)-1H-1,2,3-triazol-1-yl)phenyl)pyrimidine-2,4-diamine (WY-135), a novel ALK inhibitor, induces cell cycle arrest and apoptosis through inhibiting ALK and its downstream pathways in Karpas299 and H2228 cells Chemico-Biological Interactions ·Mengting Han,Jiwei Shen,Lijing Wang,Yu Wang,Xin Zhai,Yao Li,Meiqiao Liu,Zengqiang Li,Daiying Zuo,Yingliang Wu	2018	9
19	Synthesis, biological evaluation and molecular modeling of imidazo[1,2-a]pyridine derivatives as potent antitubulin agents Bioorganic & Medicinal Chemistry ·Jin Liu,Daiying Zuo,Tongfei Jing,Ming Guo,Lingyun Xing,Wenyu Zhang,Jianwen Zhao,Jiwei Shen,Ping Gong,Dajun Zhang,Xin Zhai	2017	16
20	Design, Synthesis and Evaluation of Novel Rhodanine‐containing Sorafenib Analogs as Potential Antitumor Agents Archiv der Pharmazie ·Wei Li,Xin Zhai,Zheng Zhong,Guang‐Yue Li,Yongxiao Pu,Ping Gong	2011	28

About Xin Zhai

Xin Zhai is a scholar working on Organic Chemistry, Molecular Biology and Oncology, having authored 66 papers that have together received 695 indexed citations. Recurring topics across this work include Synthesis and biological activity (22 papers), Cancer therapeutics and mechanisms (20 papers), Lung Cancer Treatments and Mutations (17 papers), Quinazolinone synthesis and applications (14 papers), Click Chemistry and Applications (10 papers), Lung Cancer Research Studies (8 papers), Sphingolipid Metabolism and Signaling (6 papers) and PI3K/AKT/mTOR signaling in cancer (4 papers). The work is most often cited by research in Organic Chemistry (363 citations), Toxicology (34 citations) and Oncology (153 citations). Xin Zhai has collaborated with scholars based in China and Singapore. Frequent co-authors include Ping Gong, Ming Guo, Daiying Zuo, Nan Jiang, Junjie Ma, Yanfang Zhao, Wufu Zhu, Wenfeng Gou, Lijun Xie and Tianming Zhao. Their work appears in journals such as Science Advances, Molecules and Cancer Letters.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact